This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


Researchers establish optimal immunosuppression regimen for pig-to-human kidney transplants

Researchers establish optimal immunosuppression regimen for pig-to-human kidney transplants
Credit: Journal of Clinical Investigation (2024). DOI: 10.1172/JCI175996

Currently used Food and Drug Administration-approved transplant drugs—with the addition of an also already FDA-approved complement inhibitor—are the optimal immunosuppression regimen for pig-to-human kidney transplants, according to a landmark discovery by University of Alabama at Birmingham investigators. The research is published in the Journal of Clinical Investigation.

"These findings establish the ideal immunosuppression regimen for pig-to-human kidney xenotransplantation, and it is a regimen that is already FDA-approved and that we routinely use for human-to-human allotransplantation," said Jayme Locke, professor of surgery in UAB's Marnix E. Heersink School of Medicine and lead author of the paper.

"Our research found combining common immune-suppressing drugs with a complement inhibitor effectively managed the initial human immune response against transplanted pig kidneys.

"It's a major departure from what's been tried before in most non-human primate experiments and living human heart transplants, but it's with a treatment regimen transplant doctors work with every day."

The paper marks the third major published xenotransplant finding for UAB surgeon scientists since 2022. In each case, the team used the Parsons model, a pioneering pre-clinical human research model in a recipient experiencing brain death.

The findings also continue to advance the science and promise of xenotransplantation as a therapy to potentially cure end-stage kidney disease—just as human-to-human allotransplantation can—and address the worldwide kidney organ shortage crisis. Currently, more than 800,000 people in the United States are living with kidney failure and 90,000 people are awaiting a .

Credit: University of Alabama at Birmingham

Previously, in 2022, UAB's research team announced the first peer-reviewed, published research in the American Journal of Transplantation which established that genetically modified pig kidneys were successfully transplanted into a recipient after brain death.

That groundbreaking paper also recognized the Parsons model—developed at UAB in partnership with Legacy of Hope—could evaluate the safety and feasibility of pig-to-human kidney transplants without risk to a living human. It is named for transplant pioneer Jim Parsons, an organ donor whose family generously donated his body to advance xenotransplant kidney research.

And just last summer, in a paper published in JAMA Surgery, UAB's research team established for the first time that pig kidneys could provide life-sustaining kidney function in humans.

JCI paper details

The findings in this new JCI online publication examine the case series of the three decedent model xenotransplants Locke's UAB team has conducted.

Researchers used standard immunosuppression in the first decedent model, but they did not use a complement inhibitor. While the biopsies of the pig kidneys were histologically normal in the first model after being transplanted on the first day, they began to show some signs of rejection the day after transplant.

With the second and third decedent model studies, UAB researchers used standard immunosuppression and added a complement inhibitor, which is already a common, FDA-approved regimen for patients with a rare kidney disease known as atypical hemolytic uremic syndrome or AHUS.

The complement inhibitor prevented the from forming a membrane attack complex—a microscopic battering ram that breaks through a cell's defenses, ultimately causing organ failure. Instead, when the complement inhibitor was used, the transplanted pig kidneys did not reject and were able to provide life-sustaining function.

"The membrane attack complex essentially sets up like a little drill on the surface of a cell and it drills holes in the cell," Locke said. "If you drill holes in the cell, it weakens and it dies. If you kill enough cells, then the tissue dies. If you kill enough tissue, then the organ dies. The complement inhibitor prevents the formation of this drill on the surface of the cell. It's like creating a force shield around the .

"This finding is great news. We now know that we have an FDA-approved immunosuppression regimen already available. It's a regimen that we know the patient can tolerate, and it is a treatment transplant doctors are familiar with and already know how to use. This is another critical piece that I hope will soon lead to FDA clearance for a Phase I clinical trial in living humans."

Revivicor, Inc., a subsidiary of United Therapeutics, provided the genetically-modified pigs that were the source of the investigational xenotransplant kidneys called UKidney. The 10-gene edited pigs are raised in a secure, pathogen-free facility by UAB animal care experts and are regularly tested for porcine cytomegalovirus (pCMV) and porcine endogenous retroviruses (PERV), including PERV-C. The pigs used in these studies tested negative for PERV-C and pCMV.

"Our partners at Revivicor and United Therapeutics have been incredibly supportive of Dr. Locke and our entire UAB research team, and we are grateful for the progress we have made together," said UAB Heersink School of Medicine Dean and Senior Vice President of Medicine Anupam Agarwal, M.D.

"We hope these efforts continue to move us forward toward FDA clearance for a Phase I clinical trial in living humans and hopefully add a new, desperately needed solution to address an organ shortage crisis responsible for tens of thousands of preventable deaths each year."

This xenotransplantation study was led by the Division of Transplantation in the Department of Surgery, in close partnership with Legacy of Hope. Other key contributors to this work have included members of the Division of Infectious Diseases and the Division of Nephrology in the Department of Medicine; the Department of Anesthesiology and Perioperative Medicine; and the Department of Pathology.

In addition to these specific contributors, the xenotransplantation program at UAB encompasses multiple departments and divisions of the Heersink School of Medicine and is also supported by numerous administrative and regulatory departments.

More information: Maggie E. Jones-Carr et al, C5 inhibition with eculizumab prevents thrombotic microangiopathy in a case series of pig-to-human kidney xenotransplantation, Journal of Clinical Investigation (2024). DOI: 10.1172/JCI175996

Citation: Researchers establish optimal immunosuppression regimen for pig-to-human kidney transplants (2024, January 25) retrieved 23 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Scientists transplant two gene-edited pig kidneys into human recipient


Feedback to editors